nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—ADRA1B—vas deferens—testicular cancer	0.0914	0.392	CbGeAlD
Bromocriptine—HTR7—vas deferens—testicular cancer	0.0532	0.228	CbGeAlD
Bromocriptine—ABCB1—Dactinomycin—testicular cancer	0.0301	0.172	CbGbCtD
Bromocriptine—HTR7—vein—testicular cancer	0.0226	0.097	CbGeAlD
Bromocriptine—CYP3A4—Ifosfamide—testicular cancer	0.0213	0.122	CbGbCtD
Bromocriptine—CYP1A2—Etoposide—testicular cancer	0.0195	0.111	CbGbCtD
Bromocriptine—ABCB1—Vinblastine—testicular cancer	0.0189	0.108	CbGbCtD
Bromocriptine—ABCB1—Cisplatin—testicular cancer	0.0173	0.0987	CbGbCtD
Bromocriptine—ABCB1—Etoposide—testicular cancer	0.017	0.097	CbGbCtD
Bromocriptine—HTR2A—vein—testicular cancer	0.0141	0.0605	CbGeAlD
Bromocriptine—ABCB1—Doxorubicin—testicular cancer	0.0116	0.0661	CbGbCtD
Bromocriptine—CYP3A4—Vinblastine—testicular cancer	0.0113	0.0645	CbGbCtD
Bromocriptine—ABCB1—Methotrexate—testicular cancer	0.0112	0.0641	CbGbCtD
Bromocriptine—CYP3A4—Etoposide—testicular cancer	0.0102	0.0581	CbGbCtD
Bromocriptine—CYP3A4—Doxorubicin—testicular cancer	0.00695	0.0396	CbGbCtD
Bromocriptine—DRD4—testis—testicular cancer	0.00666	0.0286	CbGeAlD
Bromocriptine—DRD5—female gonad—testicular cancer	0.00494	0.0212	CbGeAlD
Bromocriptine—ADRA2C—seminal vesicle—testicular cancer	0.00369	0.0159	CbGeAlD
Bromocriptine—ADRA2A—seminal vesicle—testicular cancer	0.00295	0.0126	CbGeAlD
Bromocriptine—HTR7—gonad—testicular cancer	0.00291	0.0125	CbGeAlD
Bromocriptine—HTR2A—embryo—testicular cancer	0.00267	0.0114	CbGeAlD
Bromocriptine—ADRA2C—female gonad—testicular cancer	0.00217	0.00931	CbGeAlD
Bromocriptine—ADRA2A—gonad—testicular cancer	0.00213	0.00914	CbGeAlD
Bromocriptine—HTR7—testis—testicular cancer	0.00209	0.00898	CbGeAlD
Bromocriptine—DRD2—testis—testicular cancer	0.00198	0.00849	CbGeAlD
Bromocriptine—ADRA2C—testis—testicular cancer	0.00192	0.00826	CbGeAlD
Bromocriptine—HTR2A—gonad—testicular cancer	0.00181	0.00777	CbGeAlD
Bromocriptine—HTR2B—lymph node—testicular cancer	0.00177	0.0076	CbGeAlD
Bromocriptine—ABCB1—embryo—testicular cancer	0.00175	0.0075	CbGeAlD
Bromocriptine—ADRA2A—female gonad—testicular cancer	0.00173	0.00743	CbGeAlD
Bromocriptine—ABCB1—seminal vesicle—testicular cancer	0.00164	0.00705	CbGeAlD
Bromocriptine—ADRA2A—testis—testicular cancer	0.00154	0.00659	CbGeAlD
Bromocriptine—ADRA2C—lymph node—testicular cancer	0.00139	0.00598	CbGeAlD
Bromocriptine—HTR2A—testis—testicular cancer	0.00131	0.0056	CbGeAlD
Bromocriptine—ABCB1—gonad—testicular cancer	0.00119	0.00509	CbGeAlD
Bromocriptine—ADRA2A—lymph node—testicular cancer	0.00111	0.00477	CbGeAlD
Bromocriptine—ABCB1—female gonad—testicular cancer	0.000965	0.00414	CbGeAlD
Bromocriptine—ABCB1—testis—testicular cancer	0.000856	0.00367	CbGeAlD
Bromocriptine—Lethargy—Doxorubicin—testicular cancer	0.000749	0.00127	CcSEcCtD
Bromocriptine—Ataxia—Epirubicin—testicular cancer	0.000745	0.00127	CcSEcCtD
Bromocriptine—Nervous system disorder—Cisplatin—testicular cancer	0.000744	0.00126	CcSEcCtD
Bromocriptine—Tachycardia—Cisplatin—testicular cancer	0.00074	0.00126	CcSEcCtD
Bromocriptine—Asthenia—Bleomycin—testicular cancer	0.000739	0.00126	CcSEcCtD
Bromocriptine—Convulsion—Etoposide—testicular cancer	0.000738	0.00125	CcSEcCtD
Bromocriptine—Skin disorder—Cisplatin—testicular cancer	0.000737	0.00125	CcSEcCtD
Bromocriptine—Hypertension—Etoposide—testicular cancer	0.000735	0.00125	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.000734	0.00125	CcSEcCtD
Bromocriptine—Diplopia—Doxorubicin—testicular cancer	0.000734	0.00125	CcSEcCtD
Bromocriptine—Feeling abnormal—Ifosfamide—testicular cancer	0.000725	0.00123	CcSEcCtD
Bromocriptine—Nausea—Vinblastine—testicular cancer	0.000724	0.00123	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Epirubicin—testicular cancer	0.000724	0.00123	CcSEcCtD
Bromocriptine—Abdominal pain upper—Epirubicin—testicular cancer	0.000724	0.00123	CcSEcCtD
Bromocriptine—Anorexia—Cisplatin—testicular cancer	0.000723	0.00123	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00072	0.00122	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00072	0.00122	CcSEcCtD
Bromocriptine—Hypotension—Cisplatin—testicular cancer	0.000709	0.00121	CcSEcCtD
Bromocriptine—Nasopharyngitis—Epirubicin—testicular cancer	0.000709	0.0012	CcSEcCtD
Bromocriptine—Abdominal discomfort—Methotrexate—testicular cancer	0.000702	0.00119	CcSEcCtD
Bromocriptine—Confusional state—Etoposide—testicular cancer	0.000701	0.00119	CcSEcCtD
Bromocriptine—Urticaria—Ifosfamide—testicular cancer	0.000699	0.00119	CcSEcCtD
Bromocriptine—Body temperature increased—Ifosfamide—testicular cancer	0.000696	0.00118	CcSEcCtD
Bromocriptine—Abdominal pain—Ifosfamide—testicular cancer	0.000696	0.00118	CcSEcCtD
Bromocriptine—Infection—Etoposide—testicular cancer	0.000691	0.00117	CcSEcCtD
Bromocriptine—Ataxia—Doxorubicin—testicular cancer	0.00069	0.00117	CcSEcCtD
Bromocriptine—Asthenia—Dactinomycin—testicular cancer	0.000689	0.00117	CcSEcCtD
Bromocriptine—Influenza—Epirubicin—testicular cancer	0.000685	0.00116	CcSEcCtD
Bromocriptine—Dysphagia—Epirubicin—testicular cancer	0.000685	0.00116	CcSEcCtD
Bromocriptine—Paraesthesia—Cisplatin—testicular cancer	0.000681	0.00116	CcSEcCtD
Bromocriptine—Tachycardia—Etoposide—testicular cancer	0.000678	0.00115	CcSEcCtD
Bromocriptine—Dyspnoea—Cisplatin—testicular cancer	0.000676	0.00115	CcSEcCtD
Bromocriptine—Skin disorder—Etoposide—testicular cancer	0.000675	0.00115	CcSEcCtD
Bromocriptine—Abdominal pain upper—Doxorubicin—testicular cancer	0.00067	0.00114	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00067	0.00114	CcSEcCtD
Bromocriptine—Anorexia—Etoposide—testicular cancer	0.000663	0.00113	CcSEcCtD
Bromocriptine—Decreased appetite—Cisplatin—testicular cancer	0.00066	0.00112	CcSEcCtD
Bromocriptine—Diarrhoea—Dactinomycin—testicular cancer	0.000657	0.00112	CcSEcCtD
Bromocriptine—Nasopharyngitis—Doxorubicin—testicular cancer	0.000656	0.00111	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000655	0.00111	CcSEcCtD
Bromocriptine—Vomiting—Bleomycin—testicular cancer	0.000655	0.00111	CcSEcCtD
Bromocriptine—Drowsiness—Methotrexate—testicular cancer	0.000653	0.00111	CcSEcCtD
Bromocriptine—Hypotension—Etoposide—testicular cancer	0.000649	0.0011	CcSEcCtD
Bromocriptine—Rash—Bleomycin—testicular cancer	0.000649	0.0011	CcSEcCtD
Bromocriptine—Dermatitis—Bleomycin—testicular cancer	0.000649	0.0011	CcSEcCtD
Bromocriptine—Influenza—Doxorubicin—testicular cancer	0.000634	0.00108	CcSEcCtD
Bromocriptine—Dysphagia—Doxorubicin—testicular cancer	0.000634	0.00108	CcSEcCtD
Bromocriptine—Pollakiuria—Epirubicin—testicular cancer	0.000633	0.00108	CcSEcCtD
Bromocriptine—Asthenia—Ifosfamide—testicular cancer	0.000631	0.00107	CcSEcCtD
Bromocriptine—Feeling abnormal—Cisplatin—testicular cancer	0.000625	0.00106	CcSEcCtD
Bromocriptine—Paraesthesia—Etoposide—testicular cancer	0.000624	0.00106	CcSEcCtD
Bromocriptine—ABCB1—lymph node—testicular cancer	0.00062	0.00266	CbGeAlD
Bromocriptine—Dyspnoea—Etoposide—testicular cancer	0.00062	0.00105	CcSEcCtD
Bromocriptine—Somnolence—Etoposide—testicular cancer	0.000618	0.00105	CcSEcCtD
Bromocriptine—Nausea—Bleomycin—testicular cancer	0.000612	0.00104	CcSEcCtD
Bromocriptine—Drowsiness—Epirubicin—testicular cancer	0.000611	0.00104	CcSEcCtD
Bromocriptine—Vomiting—Dactinomycin—testicular cancer	0.000611	0.00104	CcSEcCtD
Bromocriptine—Rash—Dactinomycin—testicular cancer	0.000606	0.00103	CcSEcCtD
Bromocriptine—Decreased appetite—Etoposide—testicular cancer	0.000604	0.00103	CcSEcCtD
Bromocriptine—Diarrhoea—Ifosfamide—testicular cancer	0.000602	0.00102	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Etoposide—testicular cancer	0.0006	0.00102	CcSEcCtD
Bromocriptine—Body temperature increased—Cisplatin—testicular cancer	0.0006	0.00102	CcSEcCtD
Bromocriptine—Fatigue—Etoposide—testicular cancer	0.000599	0.00102	CcSEcCtD
Bromocriptine—Constipation—Etoposide—testicular cancer	0.000594	0.00101	CcSEcCtD
Bromocriptine—Pollakiuria—Doxorubicin—testicular cancer	0.000586	0.000995	CcSEcCtD
Bromocriptine—Dizziness—Ifosfamide—testicular cancer	0.000582	0.000989	CcSEcCtD
Bromocriptine—Sinusitis—Epirubicin—testicular cancer	0.000573	0.000974	CcSEcCtD
Bromocriptine—Feeling abnormal—Etoposide—testicular cancer	0.000573	0.000974	CcSEcCtD
Bromocriptine—Nausea—Dactinomycin—testicular cancer	0.00057	0.00097	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Etoposide—testicular cancer	0.000568	0.000966	CcSEcCtD
Bromocriptine—Drowsiness—Doxorubicin—testicular cancer	0.000565	0.000961	CcSEcCtD
Bromocriptine—Visual impairment—Methotrexate—testicular cancer	0.000565	0.00096	CcSEcCtD
Bromocriptine—Vomiting—Ifosfamide—testicular cancer	0.00056	0.000951	CcSEcCtD
Bromocriptine—Bradycardia—Epirubicin—testicular cancer	0.000558	0.000949	CcSEcCtD
Bromocriptine—Rash—Ifosfamide—testicular cancer	0.000555	0.000943	CcSEcCtD
Bromocriptine—Dermatitis—Ifosfamide—testicular cancer	0.000554	0.000942	CcSEcCtD
Bromocriptine—Urticaria—Etoposide—testicular cancer	0.000552	0.000939	CcSEcCtD
Bromocriptine—Rhinitis—Epirubicin—testicular cancer	0.00055	0.000935	CcSEcCtD
Bromocriptine—Body temperature increased—Etoposide—testicular cancer	0.000549	0.000934	CcSEcCtD
Bromocriptine—Abdominal pain—Etoposide—testicular cancer	0.000549	0.000934	CcSEcCtD
Bromocriptine—Eye disorder—Methotrexate—testicular cancer	0.000548	0.000931	CcSEcCtD
Bromocriptine—Tinnitus—Methotrexate—testicular cancer	0.000546	0.000929	CcSEcCtD
Bromocriptine—Hypoaesthesia—Epirubicin—testicular cancer	0.000546	0.000928	CcSEcCtD
Bromocriptine—Asthenia—Cisplatin—testicular cancer	0.000544	0.000925	CcSEcCtD
Bromocriptine—Cardiac disorder—Methotrexate—testicular cancer	0.000544	0.000924	CcSEcCtD
Bromocriptine—Oedema peripheral—Epirubicin—testicular cancer	0.00054	0.000918	CcSEcCtD
Bromocriptine—Connective tissue disorder—Epirubicin—testicular cancer	0.000539	0.000916	CcSEcCtD
Bromocriptine—Angiopathy—Methotrexate—testicular cancer	0.000532	0.000904	CcSEcCtD
Bromocriptine—Sinusitis—Doxorubicin—testicular cancer	0.00053	0.000901	CcSEcCtD
Bromocriptine—Visual impairment—Epirubicin—testicular cancer	0.000528	0.000898	CcSEcCtD
Bromocriptine—Mediastinal disorder—Methotrexate—testicular cancer	0.000528	0.000898	CcSEcCtD
Bromocriptine—Nausea—Ifosfamide—testicular cancer	0.000523	0.000889	CcSEcCtD
Bromocriptine—Diarrhoea—Cisplatin—testicular cancer	0.000519	0.000882	CcSEcCtD
Bromocriptine—Alopecia—Methotrexate—testicular cancer	0.000518	0.00088	CcSEcCtD
Bromocriptine—Bradycardia—Doxorubicin—testicular cancer	0.000517	0.000878	CcSEcCtD
Bromocriptine—Mental disorder—Methotrexate—testicular cancer	0.000513	0.000873	CcSEcCtD
Bromocriptine—Eye disorder—Epirubicin—testicular cancer	0.000513	0.000871	CcSEcCtD
Bromocriptine—Tinnitus—Epirubicin—testicular cancer	0.000511	0.000869	CcSEcCtD
Bromocriptine—Cardiac disorder—Epirubicin—testicular cancer	0.000509	0.000865	CcSEcCtD
Bromocriptine—Rhinitis—Doxorubicin—testicular cancer	0.000509	0.000865	CcSEcCtD
Bromocriptine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000505	0.000858	CcSEcCtD
Bromocriptine—Oedema peripheral—Doxorubicin—testicular cancer	0.0005	0.00085	CcSEcCtD
Bromocriptine—Dysgeusia—Methotrexate—testicular cancer	0.0005	0.000849	CcSEcCtD
Bromocriptine—Asthenia—Etoposide—testicular cancer	0.000499	0.000848	CcSEcCtD
Bromocriptine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000499	0.000848	CcSEcCtD
Bromocriptine—Angiopathy—Epirubicin—testicular cancer	0.000498	0.000846	CcSEcCtD
Bromocriptine—Mediastinal disorder—Epirubicin—testicular cancer	0.000494	0.00084	CcSEcCtD
Bromocriptine—Arrhythmia—Epirubicin—testicular cancer	0.00049	0.000833	CcSEcCtD
Bromocriptine—Visual impairment—Doxorubicin—testicular cancer	0.000489	0.000831	CcSEcCtD
Bromocriptine—Alopecia—Epirubicin—testicular cancer	0.000485	0.000824	CcSEcCtD
Bromocriptine—Vomiting—Cisplatin—testicular cancer	0.000482	0.00082	CcSEcCtD
Bromocriptine—Vision blurred—Methotrexate—testicular cancer	0.000481	0.000817	CcSEcCtD
Bromocriptine—Mental disorder—Epirubicin—testicular cancer	0.00048	0.000817	CcSEcCtD
Bromocriptine—Rash—Cisplatin—testicular cancer	0.000478	0.000813	CcSEcCtD
Bromocriptine—Dermatitis—Cisplatin—testicular cancer	0.000478	0.000812	CcSEcCtD
Bromocriptine—Diarrhoea—Etoposide—testicular cancer	0.000476	0.000808	CcSEcCtD
Bromocriptine—Eye disorder—Doxorubicin—testicular cancer	0.000474	0.000806	CcSEcCtD
Bromocriptine—Tinnitus—Doxorubicin—testicular cancer	0.000473	0.000804	CcSEcCtD
Bromocriptine—Cardiac disorder—Doxorubicin—testicular cancer	0.000471	0.000801	CcSEcCtD
Bromocriptine—Tension—Epirubicin—testicular cancer	0.000468	0.000796	CcSEcCtD
Bromocriptine—Dysgeusia—Epirubicin—testicular cancer	0.000468	0.000795	CcSEcCtD
Bromocriptine—Nervousness—Epirubicin—testicular cancer	0.000464	0.000788	CcSEcCtD
Bromocriptine—Angiopathy—Doxorubicin—testicular cancer	0.00046	0.000783	CcSEcCtD
Bromocriptine—Dizziness—Etoposide—testicular cancer	0.00046	0.000781	CcSEcCtD
Bromocriptine—Muscle spasms—Epirubicin—testicular cancer	0.000459	0.00078	CcSEcCtD
Bromocriptine—Vertigo—Methotrexate—testicular cancer	0.000458	0.000779	CcSEcCtD
Bromocriptine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000457	0.000777	CcSEcCtD
Bromocriptine—Arrhythmia—Doxorubicin—testicular cancer	0.000453	0.000771	CcSEcCtD
Bromocriptine—Nausea—Cisplatin—testicular cancer	0.000451	0.000766	CcSEcCtD
Bromocriptine—Vision blurred—Epirubicin—testicular cancer	0.00045	0.000765	CcSEcCtD
Bromocriptine—Alopecia—Doxorubicin—testicular cancer	0.000448	0.000762	CcSEcCtD
Bromocriptine—Mental disorder—Doxorubicin—testicular cancer	0.000445	0.000756	CcSEcCtD
Bromocriptine—Convulsion—Methotrexate—testicular cancer	0.000442	0.000751	CcSEcCtD
Bromocriptine—Vomiting—Etoposide—testicular cancer	0.000442	0.000751	CcSEcCtD
Bromocriptine—Agitation—Epirubicin—testicular cancer	0.000439	0.000746	CcSEcCtD
Bromocriptine—Rash—Etoposide—testicular cancer	0.000438	0.000745	CcSEcCtD
Bromocriptine—Dermatitis—Etoposide—testicular cancer	0.000438	0.000744	CcSEcCtD
Bromocriptine—Headache—Etoposide—testicular cancer	0.000435	0.00074	CcSEcCtD
Bromocriptine—Tension—Doxorubicin—testicular cancer	0.000433	0.000737	CcSEcCtD
Bromocriptine—Dysgeusia—Doxorubicin—testicular cancer	0.000433	0.000735	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000431	0.000733	CcSEcCtD
Bromocriptine—Nervousness—Doxorubicin—testicular cancer	0.000429	0.000729	CcSEcCtD
Bromocriptine—Vertigo—Epirubicin—testicular cancer	0.000429	0.000729	CcSEcCtD
Bromocriptine—Syncope—Epirubicin—testicular cancer	0.000428	0.000728	CcSEcCtD
Bromocriptine—Muscle spasms—Doxorubicin—testicular cancer	0.000425	0.000722	CcSEcCtD
Bromocriptine—Confusional state—Methotrexate—testicular cancer	0.00042	0.000714	CcSEcCtD
Bromocriptine—Loss of consciousness—Epirubicin—testicular cancer	0.00042	0.000713	CcSEcCtD
Bromocriptine—Vision blurred—Doxorubicin—testicular cancer	0.000416	0.000708	CcSEcCtD
Bromocriptine—Convulsion—Epirubicin—testicular cancer	0.000414	0.000703	CcSEcCtD
Bromocriptine—Infection—Methotrexate—testicular cancer	0.000414	0.000703	CcSEcCtD
Bromocriptine—Nausea—Etoposide—testicular cancer	0.000413	0.000702	CcSEcCtD
Bromocriptine—Hypertension—Epirubicin—testicular cancer	0.000412	0.000701	CcSEcCtD
Bromocriptine—Nervous system disorder—Methotrexate—testicular cancer	0.000408	0.000694	CcSEcCtD
Bromocriptine—Agitation—Doxorubicin—testicular cancer	0.000406	0.00069	CcSEcCtD
Bromocriptine—Anxiety—Epirubicin—testicular cancer	0.000405	0.000688	CcSEcCtD
Bromocriptine—Skin disorder—Methotrexate—testicular cancer	0.000404	0.000687	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000404	0.000686	CcSEcCtD
Bromocriptine—Dry mouth—Epirubicin—testicular cancer	0.000397	0.000676	CcSEcCtD
Bromocriptine—Vertigo—Doxorubicin—testicular cancer	0.000397	0.000675	CcSEcCtD
Bromocriptine—Anorexia—Methotrexate—testicular cancer	0.000397	0.000675	CcSEcCtD
Bromocriptine—Syncope—Doxorubicin—testicular cancer	0.000396	0.000673	CcSEcCtD
Bromocriptine—Confusional state—Epirubicin—testicular cancer	0.000393	0.000668	CcSEcCtD
Bromocriptine—Oedema—Epirubicin—testicular cancer	0.00039	0.000662	CcSEcCtD
Bromocriptine—Hypotension—Methotrexate—testicular cancer	0.000389	0.000661	CcSEcCtD
Bromocriptine—Loss of consciousness—Doxorubicin—testicular cancer	0.000388	0.00066	CcSEcCtD
Bromocriptine—Infection—Epirubicin—testicular cancer	0.000387	0.000658	CcSEcCtD
Bromocriptine—Shock—Epirubicin—testicular cancer	0.000383	0.000652	CcSEcCtD
Bromocriptine—Convulsion—Doxorubicin—testicular cancer	0.000383	0.000651	CcSEcCtD
Bromocriptine—Nervous system disorder—Epirubicin—testicular cancer	0.000382	0.000649	CcSEcCtD
Bromocriptine—Hypertension—Doxorubicin—testicular cancer	0.000381	0.000648	CcSEcCtD
Bromocriptine—Tachycardia—Epirubicin—testicular cancer	0.00038	0.000646	CcSEcCtD
Bromocriptine—Skin disorder—Epirubicin—testicular cancer	0.000378	0.000643	CcSEcCtD
Bromocriptine—Insomnia—Methotrexate—testicular cancer	0.000377	0.00064	CcSEcCtD
Bromocriptine—Anxiety—Doxorubicin—testicular cancer	0.000375	0.000637	CcSEcCtD
Bromocriptine—Paraesthesia—Methotrexate—testicular cancer	0.000374	0.000635	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000373	0.000635	CcSEcCtD
Bromocriptine—Anorexia—Epirubicin—testicular cancer	0.000371	0.000631	CcSEcCtD
Bromocriptine—Dyspnoea—Methotrexate—testicular cancer	0.000371	0.000631	CcSEcCtD
Bromocriptine—Somnolence—Methotrexate—testicular cancer	0.00037	0.000629	CcSEcCtD
Bromocriptine—Dry mouth—Doxorubicin—testicular cancer	0.000368	0.000625	CcSEcCtD
Bromocriptine—Dyspepsia—Methotrexate—testicular cancer	0.000366	0.000623	CcSEcCtD
Bromocriptine—Hypotension—Epirubicin—testicular cancer	0.000364	0.000619	CcSEcCtD
Bromocriptine—Confusional state—Doxorubicin—testicular cancer	0.000364	0.000618	CcSEcCtD
Bromocriptine—Decreased appetite—Methotrexate—testicular cancer	0.000362	0.000615	CcSEcCtD
Bromocriptine—Oedema—Doxorubicin—testicular cancer	0.000361	0.000613	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000359	0.000611	CcSEcCtD
Bromocriptine—Fatigue—Methotrexate—testicular cancer	0.000359	0.00061	CcSEcCtD
Bromocriptine—Infection—Doxorubicin—testicular cancer	0.000358	0.000609	CcSEcCtD
Bromocriptine—Shock—Doxorubicin—testicular cancer	0.000355	0.000603	CcSEcCtD
Bromocriptine—Nervous system disorder—Doxorubicin—testicular cancer	0.000354	0.000601	CcSEcCtD
Bromocriptine—Insomnia—Epirubicin—testicular cancer	0.000352	0.000599	CcSEcCtD
Bromocriptine—Tachycardia—Doxorubicin—testicular cancer	0.000352	0.000598	CcSEcCtD
Bromocriptine—Skin disorder—Doxorubicin—testicular cancer	0.00035	0.000595	CcSEcCtD
Bromocriptine—Paraesthesia—Epirubicin—testicular cancer	0.00035	0.000595	CcSEcCtD
Bromocriptine—Dyspnoea—Epirubicin—testicular cancer	0.000347	0.00059	CcSEcCtD
Bromocriptine—Somnolence—Epirubicin—testicular cancer	0.000346	0.000589	CcSEcCtD
Bromocriptine—Anorexia—Doxorubicin—testicular cancer	0.000344	0.000584	CcSEcCtD
Bromocriptine—Feeling abnormal—Methotrexate—testicular cancer	0.000343	0.000583	CcSEcCtD
Bromocriptine—Dyspepsia—Epirubicin—testicular cancer	0.000343	0.000583	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Methotrexate—testicular cancer	0.00034	0.000579	CcSEcCtD
Bromocriptine—Decreased appetite—Epirubicin—testicular cancer	0.000339	0.000576	CcSEcCtD
Bromocriptine—Hypotension—Doxorubicin—testicular cancer	0.000337	0.000573	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000336	0.000572	CcSEcCtD
Bromocriptine—Fatigue—Epirubicin—testicular cancer	0.000336	0.000571	CcSEcCtD
Bromocriptine—Constipation—Epirubicin—testicular cancer	0.000333	0.000566	CcSEcCtD
Bromocriptine—Urticaria—Methotrexate—testicular cancer	0.000331	0.000562	CcSEcCtD
Bromocriptine—Body temperature increased—Methotrexate—testicular cancer	0.000329	0.000559	CcSEcCtD
Bromocriptine—Abdominal pain—Methotrexate—testicular cancer	0.000329	0.000559	CcSEcCtD
Bromocriptine—Insomnia—Doxorubicin—testicular cancer	0.000326	0.000554	CcSEcCtD
Bromocriptine—Paraesthesia—Doxorubicin—testicular cancer	0.000324	0.00055	CcSEcCtD
Bromocriptine—Dyspnoea—Doxorubicin—testicular cancer	0.000321	0.000546	CcSEcCtD
Bromocriptine—Feeling abnormal—Epirubicin—testicular cancer	0.000321	0.000546	CcSEcCtD
Bromocriptine—Somnolence—Doxorubicin—testicular cancer	0.00032	0.000545	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000319	0.000542	CcSEcCtD
Bromocriptine—Dyspepsia—Doxorubicin—testicular cancer	0.000317	0.000539	CcSEcCtD
Bromocriptine—Decreased appetite—Doxorubicin—testicular cancer	0.000313	0.000533	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000311	0.000529	CcSEcCtD
Bromocriptine—Fatigue—Doxorubicin—testicular cancer	0.000311	0.000528	CcSEcCtD
Bromocriptine—Urticaria—Epirubicin—testicular cancer	0.00031	0.000526	CcSEcCtD
Bromocriptine—Constipation—Doxorubicin—testicular cancer	0.000308	0.000524	CcSEcCtD
Bromocriptine—Abdominal pain—Epirubicin—testicular cancer	0.000308	0.000524	CcSEcCtD
Bromocriptine—Body temperature increased—Epirubicin—testicular cancer	0.000308	0.000524	CcSEcCtD
Bromocriptine—Asthenia—Methotrexate—testicular cancer	0.000299	0.000508	CcSEcCtD
Bromocriptine—Feeling abnormal—Doxorubicin—testicular cancer	0.000297	0.000505	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000295	0.000501	CcSEcCtD
Bromocriptine—Urticaria—Doxorubicin—testicular cancer	0.000286	0.000487	CcSEcCtD
Bromocriptine—Abdominal pain—Doxorubicin—testicular cancer	0.000285	0.000484	CcSEcCtD
Bromocriptine—Body temperature increased—Doxorubicin—testicular cancer	0.000285	0.000484	CcSEcCtD
Bromocriptine—Diarrhoea—Methotrexate—testicular cancer	0.000285	0.000484	CcSEcCtD
Bromocriptine—Asthenia—Epirubicin—testicular cancer	0.00028	0.000475	CcSEcCtD
Bromocriptine—Dizziness—Methotrexate—testicular cancer	0.000275	0.000468	CcSEcCtD
Bromocriptine—Diarrhoea—Epirubicin—testicular cancer	0.000267	0.000453	CcSEcCtD
Bromocriptine—Vomiting—Methotrexate—testicular cancer	0.000265	0.00045	CcSEcCtD
Bromocriptine—Rash—Methotrexate—testicular cancer	0.000263	0.000446	CcSEcCtD
Bromocriptine—Dermatitis—Methotrexate—testicular cancer	0.000262	0.000446	CcSEcCtD
Bromocriptine—Headache—Methotrexate—testicular cancer	0.000261	0.000443	CcSEcCtD
Bromocriptine—Asthenia—Doxorubicin—testicular cancer	0.000259	0.00044	CcSEcCtD
Bromocriptine—Dizziness—Epirubicin—testicular cancer	0.000258	0.000438	CcSEcCtD
Bromocriptine—Vomiting—Epirubicin—testicular cancer	0.000248	0.000421	CcSEcCtD
Bromocriptine—Nausea—Methotrexate—testicular cancer	0.000247	0.00042	CcSEcCtD
Bromocriptine—Diarrhoea—Doxorubicin—testicular cancer	0.000247	0.000419	CcSEcCtD
Bromocriptine—Rash—Epirubicin—testicular cancer	0.000246	0.000418	CcSEcCtD
Bromocriptine—Dermatitis—Epirubicin—testicular cancer	0.000245	0.000417	CcSEcCtD
Bromocriptine—Headache—Epirubicin—testicular cancer	0.000244	0.000415	CcSEcCtD
Bromocriptine—Dizziness—Doxorubicin—testicular cancer	0.000238	0.000405	CcSEcCtD
Bromocriptine—Nausea—Epirubicin—testicular cancer	0.000231	0.000393	CcSEcCtD
Bromocriptine—Vomiting—Doxorubicin—testicular cancer	0.000229	0.00039	CcSEcCtD
Bromocriptine—Rash—Doxorubicin—testicular cancer	0.000227	0.000386	CcSEcCtD
Bromocriptine—Dermatitis—Doxorubicin—testicular cancer	0.000227	0.000386	CcSEcCtD
Bromocriptine—Headache—Doxorubicin—testicular cancer	0.000226	0.000384	CcSEcCtD
Bromocriptine—Nausea—Doxorubicin—testicular cancer	0.000214	0.000364	CcSEcCtD
Bromocriptine—DRD5—G alpha (s) signalling events—INSL3—testicular cancer	0.000126	0.0395	CbGpPWpGaD
Bromocriptine—HTR6—G alpha (s) signalling events—INSL3—testicular cancer	9.72e-05	0.0305	CbGpPWpGaD
Bromocriptine—HTR7—G alpha (s) signalling events—INSL3—testicular cancer	9.71e-05	0.0304	CbGpPWpGaD
Bromocriptine—DRD1—G alpha (s) signalling events—INSL3—testicular cancer	8.37e-05	0.0262	CbGpPWpGaD
Bromocriptine—ADRB1—G alpha (s) signalling events—INSL3—testicular cancer	7.52e-05	0.0236	CbGpPWpGaD
Bromocriptine—DRD5—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.01e-05	0.0188	CbGpPWpGaD
Bromocriptine—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.64e-05	0.0145	CbGpPWpGaD
Bromocriptine—HTR7—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.63e-05	0.0145	CbGpPWpGaD
Bromocriptine—HTR1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.6e-05	0.0144	CbGpPWpGaD
Bromocriptine—DRD5—GPCR ligand binding—INSL3—testicular cancer	4.57e-05	0.0143	CbGpPWpGaD
Bromocriptine—HTR1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.5e-05	0.0141	CbGpPWpGaD
Bromocriptine—DRD4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.43e-05	0.0139	CbGpPWpGaD
Bromocriptine—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.23e-05	0.0133	CbGpPWpGaD
Bromocriptine—DRD1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.99e-05	0.0125	CbGpPWpGaD
Bromocriptine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.94e-05	0.0123	CbGpPWpGaD
Bromocriptine—DRD3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.94e-05	0.0123	CbGpPWpGaD
Bromocriptine—ADRB1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.59e-05	0.0112	CbGpPWpGaD
Bromocriptine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.55e-05	0.0111	CbGpPWpGaD
Bromocriptine—HTR6—GPCR ligand binding—INSL3—testicular cancer	3.53e-05	0.0111	CbGpPWpGaD
Bromocriptine—HTR7—GPCR ligand binding—INSL3—testicular cancer	3.53e-05	0.011	CbGpPWpGaD
Bromocriptine—HTR1D—GPCR ligand binding—INSL3—testicular cancer	3.5e-05	0.011	CbGpPWpGaD
Bromocriptine—ADRA1B—AMPK Signaling—STK11—testicular cancer	3.49e-05	0.0109	CbGpPWpGaD
Bromocriptine—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.43e-05	0.0107	CbGpPWpGaD
Bromocriptine—HTR1B—GPCR ligand binding—INSL3—testicular cancer	3.43e-05	0.0107	CbGpPWpGaD
Bromocriptine—HTR2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.41e-05	0.0107	CbGpPWpGaD
Bromocriptine—DRD4—GPCR ligand binding—INSL3—testicular cancer	3.38e-05	0.0106	CbGpPWpGaD
Bromocriptine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.32e-05	0.0104	CbGpPWpGaD
Bromocriptine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.27e-05	0.0102	CbGpPWpGaD
Bromocriptine—HTR2B—GPCR ligand binding—INSL3—testicular cancer	3.22e-05	0.0101	CbGpPWpGaD
Bromocriptine—ADRA1A—AMPK Signaling—STK11—testicular cancer	3.1e-05	0.0097	CbGpPWpGaD
Bromocriptine—DRD1—GPCR ligand binding—INSL3—testicular cancer	3.04e-05	0.00952	CbGpPWpGaD
Bromocriptine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	3.02e-05	0.00947	CbGpPWpGaD
Bromocriptine—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	3.01e-05	0.00944	CbGpPWpGaD
Bromocriptine—ADRA1D—GPCR ligand binding—INSL3—testicular cancer	3e-05	0.00939	CbGpPWpGaD
Bromocriptine—DRD3—GPCR ligand binding—INSL3—testicular cancer	3e-05	0.00939	CbGpPWpGaD
Bromocriptine—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	2.96e-05	0.00929	CbGpPWpGaD
Bromocriptine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	2.9e-05	0.00909	CbGpPWpGaD
Bromocriptine—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	2.83e-05	0.00886	CbGpPWpGaD
Bromocriptine—ADRB1—GPCR ligand binding—INSL3—testicular cancer	2.73e-05	0.00856	CbGpPWpGaD
Bromocriptine—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	2.71e-05	0.00848	CbGpPWpGaD
Bromocriptine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	2.7e-05	0.00845	CbGpPWpGaD
Bromocriptine—HTR1A—GPCR ligand binding—INSL3—testicular cancer	2.61e-05	0.00819	CbGpPWpGaD
Bromocriptine—HTR2C—GPCR ligand binding—INSL3—testicular cancer	2.6e-05	0.00814	CbGpPWpGaD
Bromocriptine—DRD5—GPCR downstream signaling—INSL3—testicular cancer	2.58e-05	0.0081	CbGpPWpGaD
Bromocriptine—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	2.55e-05	0.00799	CbGpPWpGaD
Bromocriptine—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	2.53e-05	0.00792	CbGpPWpGaD
Bromocriptine—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	2.49e-05	0.0078	CbGpPWpGaD
Bromocriptine—DRD5—Signaling by GPCR—INSL3—testicular cancer	2.35e-05	0.00735	CbGpPWpGaD
Bromocriptine—DRD2—GPCR ligand binding—INSL3—testicular cancer	2.29e-05	0.00719	CbGpPWpGaD
Bromocriptine—HTR2A—GPCR ligand binding—INSL3—testicular cancer	2.26e-05	0.00707	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	2.21e-05	0.00692	CbGpPWpGaD
Bromocriptine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	2.07e-05	0.00649	CbGpPWpGaD
Bromocriptine—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	2.07e-05	0.00649	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	2.05e-05	0.00643	CbGpPWpGaD
Bromocriptine—HTR6—GPCR downstream signaling—INSL3—testicular cancer	1.99e-05	0.00625	CbGpPWpGaD
Bromocriptine—HTR7—GPCR downstream signaling—INSL3—testicular cancer	1.99e-05	0.00624	CbGpPWpGaD
Bromocriptine—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	1.98e-05	0.0062	CbGpPWpGaD
Bromocriptine—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	1.94e-05	0.00607	CbGpPWpGaD
Bromocriptine—DRD4—GPCR downstream signaling—INSL3—testicular cancer	1.91e-05	0.00598	CbGpPWpGaD
Bromocriptine—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	1.82e-05	0.0057	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—INSL3—testicular cancer	1.81e-05	0.00567	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—INSL3—testicular cancer	1.81e-05	0.00567	CbGpPWpGaD
Bromocriptine—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	1.8e-05	0.00564	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—INSL3—testicular cancer	1.8e-05	0.00563	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—INSL3—testicular cancer	1.76e-05	0.00551	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—INSL3—testicular cancer	1.73e-05	0.00543	CbGpPWpGaD
Bromocriptine—DRD1—GPCR downstream signaling—INSL3—testicular cancer	1.72e-05	0.00538	CbGpPWpGaD
Bromocriptine—ADRA1D—GPCR downstream signaling—INSL3—testicular cancer	1.69e-05	0.00531	CbGpPWpGaD
Bromocriptine—DRD3—GPCR downstream signaling—INSL3—testicular cancer	1.69e-05	0.00531	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—INSL3—testicular cancer	1.65e-05	0.00518	CbGpPWpGaD
Bromocriptine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.65e-05	0.00517	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—INSL3—testicular cancer	1.56e-05	0.00488	CbGpPWpGaD
Bromocriptine—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	1.54e-05	0.00484	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—INSL3—testicular cancer	1.54e-05	0.00482	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—INSL3—testicular cancer	1.54e-05	0.00482	CbGpPWpGaD
Bromocriptine—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	1.53e-05	0.00479	CbGpPWpGaD
Bromocriptine—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	1.48e-05	0.00463	CbGpPWpGaD
Bromocriptine—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	1.47e-05	0.0046	CbGpPWpGaD
Bromocriptine—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	1.43e-05	0.00448	CbGpPWpGaD
Bromocriptine—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	1.41e-05	0.00441	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—INSL3—testicular cancer	1.4e-05	0.00439	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	1.39e-05	0.00435	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—INSL3—testicular cancer	1.39e-05	0.00434	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—INSL3—testicular cancer	1.34e-05	0.0042	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—INSL3—testicular cancer	1.33e-05	0.00418	CbGpPWpGaD
Bromocriptine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.33e-05	0.00416	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	1.3e-05	0.00406	CbGpPWpGaD
Bromocriptine—DRD2—GPCR downstream signaling—INSL3—testicular cancer	1.3e-05	0.00406	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	1.28e-05	0.004	CbGpPWpGaD
Bromocriptine—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	1.28e-05	0.004	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	1.25e-05	0.00391	CbGpPWpGaD
Bromocriptine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.21e-05	0.0038	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—INSL3—testicular cancer	1.18e-05	0.00369	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	1.16e-05	0.00364	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—INSL3—testicular cancer	1.16e-05	0.00363	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	1.13e-05	0.00355	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00335	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00335	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—INSL3—testicular cancer	1.06e-05	0.00333	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	1.05e-05	0.0033	CbGpPWpGaD
Bromocriptine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.05e-05	0.0033	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—INSL3—testicular cancer	1.04e-05	0.00326	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—INSL3—testicular cancer	1.02e-05	0.00321	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—INSL3—testicular cancer	9.77e-06	0.00306	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—INSL3—testicular cancer	9.21e-06	0.00289	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—INSL3—testicular cancer	9.09e-06	0.00285	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—INSL3—testicular cancer	9.09e-06	0.00285	CbGpPWpGaD
Bromocriptine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	8.81e-06	0.00276	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—INSL3—testicular cancer	8.28e-06	0.00259	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—INSL3—testicular cancer	8.21e-06	0.00257	CbGpPWpGaD
Bromocriptine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	8.12e-06	0.00255	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—INSL3—testicular cancer	7.92e-06	0.00248	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—INSL3—testicular cancer	7.88e-06	0.00247	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—INSL3—testicular cancer	7.67e-06	0.0024	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—INSL3—testicular cancer	7.54e-06	0.00236	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—INSL3—testicular cancer	6.95e-06	0.00218	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—INSL3—testicular cancer	6.84e-06	0.00214	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	6.7e-06	0.0021	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	6.23e-06	0.00195	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—H2AFZ—testicular cancer	4.44e-06	0.00139	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—STK11—testicular cancer	4.41e-06	0.00138	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—KITLG—testicular cancer	4.08e-06	0.00128	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.04e-06	0.00127	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—HPGDS—testicular cancer	4.02e-06	0.00126	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—H2AFZ—testicular cancer	3.43e-06	0.00107	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—H2AFZ—testicular cancer	3.42e-06	0.00107	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—STK11—testicular cancer	3.41e-06	0.00107	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—STK11—testicular cancer	3.4e-06	0.00107	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	3.4e-06	0.00106	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—STK11—testicular cancer	3.38e-06	0.00106	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	3.33e-06	0.00104	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—STK11—testicular cancer	3.31e-06	0.00104	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—H2AFZ—testicular cancer	3.28e-06	0.00103	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—HPGDS—testicular cancer	3.26e-06	0.00102	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—STK11—testicular cancer	3.26e-06	0.00102	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—KITLG—testicular cancer	3.15e-06	0.000987	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—KITLG—testicular cancer	3.15e-06	0.000986	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—KITLG—testicular cancer	3.13e-06	0.00098	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	3.13e-06	0.000979	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—STK11—testicular cancer	3.11e-06	0.000974	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—KITLG—testicular cancer	3.06e-06	0.000959	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—FGFR3—testicular cancer	3.03e-06	0.000951	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—KITLG—testicular cancer	3.01e-06	0.000944	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—H2AFZ—testicular cancer	2.95e-06	0.000924	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—STK11—testicular cancer	2.93e-06	0.000918	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—STK11—testicular cancer	2.92e-06	0.000914	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—H2AFZ—testicular cancer	2.91e-06	0.000911	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—H2AFZ—testicular cancer	2.91e-06	0.000911	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—STK11—testicular cancer	2.89e-06	0.000906	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—STK11—testicular cancer	2.89e-06	0.000906	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—KITLG—testicular cancer	2.88e-06	0.000901	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—KIT—testicular cancer	2.79e-06	0.000873	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—KITLG—testicular cancer	2.71e-06	0.00085	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—KITLG—testicular cancer	2.68e-06	0.000838	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—KITLG—testicular cancer	2.68e-06	0.000838	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	2.65e-06	0.00083	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—STK11—testicular cancer	2.64e-06	0.000826	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	2.63e-06	0.000823	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—STK11—testicular cancer	2.61e-06	0.000818	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	2.54e-06	0.000794	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	2.52e-06	0.00079	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—STK11—testicular cancer	2.52e-06	0.00079	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—STK11—testicular cancer	2.51e-06	0.000786	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	2.45e-06	0.000769	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—STK11—testicular cancer	2.44e-06	0.000764	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—KITLG—testicular cancer	2.44e-06	0.000764	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—KITLG—testicular cancer	2.42e-06	0.000757	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	2.41e-06	0.000756	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—STK11—testicular cancer	2.4e-06	0.000752	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—STK11—testicular cancer	2.37e-06	0.000742	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—FGFR3—testicular cancer	2.34e-06	0.000734	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—FGFR3—testicular cancer	2.34e-06	0.000733	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—KITLG—testicular cancer	2.33e-06	0.000731	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—FGFR3—testicular cancer	2.32e-06	0.000728	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—KITLG—testicular cancer	2.32e-06	0.000727	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—FGFR3—testicular cancer	2.28e-06	0.000713	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—KITLG—testicular cancer	2.26e-06	0.000707	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—HPGDS—testicular cancer	2.26e-06	0.000706	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—FGFR3—testicular cancer	2.24e-06	0.000702	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	2.23e-06	0.000697	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—KITLG—testicular cancer	2.22e-06	0.000696	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—STK11—testicular cancer	2.21e-06	0.000693	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	2.19e-06	0.000686	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—STK11—testicular cancer	2.18e-06	0.000682	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—KIT—testicular cancer	2.15e-06	0.000674	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—KIT—testicular cancer	2.15e-06	0.000673	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	2.14e-06	0.000672	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—FGFR3—testicular cancer	2.14e-06	0.00067	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—KIT—testicular cancer	2.13e-06	0.000668	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—STK11—testicular cancer	2.13e-06	0.000668	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—KIT—testicular cancer	2.09e-06	0.000655	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—KIT—testicular cancer	2.06e-06	0.000644	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—KITLG—testicular cancer	2.05e-06	0.000642	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—FGFR3—testicular cancer	2.02e-06	0.000632	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—KITLG—testicular cancer	2.02e-06	0.000631	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	1.99e-06	0.000624	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—FGFR3—testicular cancer	1.99e-06	0.000623	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—FGFR3—testicular cancer	1.99e-06	0.000623	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—STK11—testicular cancer	1.98e-06	0.000621	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	1.97e-06	0.000618	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—KIT—testicular cancer	1.96e-06	0.000615	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—KIT—testicular cancer	1.85e-06	0.00058	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	1.83e-06	0.000574	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—KIT—testicular cancer	1.83e-06	0.000572	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—KIT—testicular cancer	1.83e-06	0.000572	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—FGFR3—testicular cancer	1.81e-06	0.000568	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—HPGDS—testicular cancer	1.8e-06	0.000564	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	1.8e-06	0.000563	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—FGFR3—testicular cancer	1.73e-06	0.000543	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—FGFR3—testicular cancer	1.72e-06	0.00054	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	1.68e-06	0.000526	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—KIT—testicular cancer	1.66e-06	0.000521	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	1.65e-06	0.000517	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—KIT—testicular cancer	1.65e-06	0.000517	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—STK11—testicular cancer	1.64e-06	0.000513	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—KIT—testicular cancer	1.59e-06	0.000499	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—KIT—testicular cancer	1.58e-06	0.000496	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—KIT—testicular cancer	1.54e-06	0.000482	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—FGFR3—testicular cancer	1.52e-06	0.000477	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—KIT—testicular cancer	1.52e-06	0.000475	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—FGFR3—testicular cancer	1.5e-06	0.000469	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	1.47e-06	0.000459	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—KIT—testicular cancer	1.4e-06	0.000438	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—HPGDS—testicular cancer	1.39e-06	0.000435	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—KIT—testicular cancer	1.38e-06	0.000431	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	1.36e-06	0.000427	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—KIT—testicular cancer	1.35e-06	0.000422	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—STK11—testicular cancer	1.31e-06	0.00041	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—KIT—testicular cancer	1.25e-06	0.000392	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—STK11—testicular cancer	1.01e-06	0.000316	CbGpPWpGaD
